Skip to main navigation
Top
Skip to main content
Agios Logo Agios Logo
  • About Us

    About Us

    • Values
    • History
    • Leadership
    • Corporate Social Responsibility
    • Access to Medicines
    • News
      About Us
    • Values

    • History

    • Leadership

    • Corporate Social Responsibility

    • Access to Medicines

    • News

  • Genetically Defined Diseases

    Genetically Defined Diseases

    • Pyruvate Kinase Deficiency
    • Thalassemia
    • Sickle Cell Disease
    • Our Science
      Genetically Defined Diseases
    • Pyruvate Kinase Deficiency

    • Thalassemia

    • Sickle Cell Disease

    • Our Science

  • Pipeline

    Pipeline

  • Our Medicine

    Our Medicine

  • Patients & Partners

    Patients & Partners

    • Patients & Caregivers
      • Clinical Trials

      • Patient Resources

    • Healthcare Providers

      • Clinical Data Sharing

    • Partner Opportunities

        Patients & Partners
      • Patients & Caregivers

        • Clinical Trials

        • Patient Resources

      • Healthcare Providers

        • Clinical Data Sharing

      • Partner Opportunities

      • Investors

        Investors

        • News & Events
        • Stock Information
        • Corporate Governance
        • Financials
        • IR Resources

          Investors

        • News & Events

        • Stock Information

        • Corporate Governance

        • Financials

        • IR Resources

      • Inside Agios

        Inside Agios

        • Careers

        • Culture

        • Diversity

        • Commitment to Community

        • Benefits

          Inside Agios
        • Careers

        • Culture

        • Diversity

        • Commitment to Community

        • Benefits

      Press Releases

      • Investors Overview
      • News & Events
        • Press Releases
        • Publications
        • Events & Presentations
      • Stock Information
      • Corporate Governance
        • Leadership
        • Board of Directors
        • Corporate Fact Sheet
        • Environment, Social and Governance (ESG) Report
      • Financials
        • SEC Filings
        • Annual Reports & Proxy
        • Quarterly Results
      • IR Resources
        • Investor FAQs
        • IR Contact
        • Information Request
        • Email Alerts
      Feb 02, 2023
      Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023
      Read More
      PDF Version
      Jan 08, 2023
      Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company’s Vision to Transform Patient Outcomes in Rare Diseases
      Read More
      PDF Version
      Jan 03, 2023
      Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer
      Read More
      PDF Version
      • latest-earnings-call Latest Earnings Call View Replay
      • latest-form-10-k Latest Form 10-K View PDF
      • email-alerts Email Alerts Sign Up
      • corporate-fact-sheet Corporate Fact Sheet View PDF
      • corporate-responsibility Corporate Responsibility View PDF

      Connect with us on LinkedIn or follow us on Twitter as we push forward into changing the landscape for people with genetically defined diseases.

      LinkedIn logo Connect on LinkedIn
      Twitter logo Follow us our Twitter
      • Contact
      • About Us
      • Patients & Partners
      • Careers
      Agios Logo

      Agios Pharmaceuticals, Inc. © 2023

      All right reserved.

      • Cookies Preferences
      • Copyright Info
      • Compliance
      • Sitemap
      • Privacy Notice
      • Terms of Use